vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Ares Commercial Real Estate Corp is the larger business by last-quarter revenue ($13.2M vs $12.6M, roughly 1.1× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -29.2%, a 279.9% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -24.5%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -15.9%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
ACRE vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $12.6M |
| Net Profit | $-3.9M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | -29.2% | — |
| Net Margin | -29.2% | 250.7% |
| Revenue YoY | -24.5% | 24080.8% |
| Net Profit YoY | 63.8% | 250.9% |
| EPS (diluted) | — | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $12.6M | ||
| Q3 25 | $14.1M | $0 | ||
| Q2 25 | $12.6M | $0 | ||
| Q1 25 | $14.9M | $12.0K | ||
| Q4 24 | $17.5M | $52.0K | ||
| Q3 24 | $16.7M | $65.0K | ||
| Q2 24 | $16.8M | $114.0K | ||
| Q1 24 | $18.7M | $140.0K |
| Q4 25 | $-3.9M | $31.5M | ||
| Q3 25 | $4.7M | $-7.4M | ||
| Q2 25 | $-11.0M | $-1.7M | ||
| Q1 25 | $9.3M | $-13.9M | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-5.9M | $-17.1M | ||
| Q2 24 | $-6.1M | $-17.9M | ||
| Q1 24 | $-12.3M | $-12.7M |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | — | ||
| Q1 25 | 64.4% | -122758.3% | ||
| Q4 24 | -61.0% | — | ||
| Q3 24 | -35.3% | -28604.6% | ||
| Q2 24 | -36.5% | -16720.2% | ||
| Q1 24 | -65.9% | -9987.1% |
| Q4 25 | -29.2% | 250.7% | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | -87.8% | — | ||
| Q1 25 | 62.5% | -115550.0% | ||
| Q4 24 | -60.9% | — | ||
| Q3 24 | -35.3% | -26380.0% | ||
| Q2 24 | -36.5% | -15668.4% | ||
| Q1 24 | -65.9% | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.25 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.32 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $40.3M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $59.0M |
| Total Assets | $1.6B | $68.9M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $40.3M | ||
| Q3 25 | $84.9M | $48.6M | ||
| Q2 25 | $90.0M | $31.2M | ||
| Q1 25 | $125.5M | $48.9M | ||
| Q4 24 | $63.8M | $52.9M | ||
| Q3 24 | $68.9M | $76.3M | ||
| Q2 24 | $70.6M | $63.5M | ||
| Q1 24 | $99.5M | $82.3M |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | $59.0M | ||
| Q3 25 | $521.0M | $26.5M | ||
| Q2 25 | $523.7M | $32.8M | ||
| Q1 25 | $542.1M | $33.8M | ||
| Q4 24 | $540.1M | $46.1M | ||
| Q3 24 | $563.8M | $65.5M | ||
| Q2 24 | $582.3M | $80.5M | ||
| Q1 24 | $601.1M | $96.2M |
| Q4 25 | $1.6B | $68.9M | ||
| Q3 25 | $1.4B | $54.2M | ||
| Q2 25 | $1.4B | $62.1M | ||
| Q1 25 | $1.5B | $77.7M | ||
| Q4 24 | $1.8B | $110.5M | ||
| Q3 24 | $1.9B | $135.2M | ||
| Q2 24 | $2.1B | $149.9M | ||
| Q1 24 | $2.1B | $167.7M |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $-8.4M | ||
| Q3 25 | $3.8M | $17.4M | ||
| Q2 25 | $4.9M | $-17.7M | ||
| Q1 25 | $8.0M | $-4.0M | ||
| Q4 24 | $35.5M | $-23.4M | ||
| Q3 24 | $8.4M | $12.8M | ||
| Q2 24 | $8.7M | $-18.7M | ||
| Q1 24 | $11.4M | $5.9M |
| Q4 25 | — | -0.26× | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
